全文获取类型
收费全文 | 2392218篇 |
免费 | 177769篇 |
国内免费 | 3350篇 |
专业分类
耳鼻咽喉 | 32808篇 |
儿科学 | 77311篇 |
妇产科学 | 63822篇 |
基础医学 | 354977篇 |
口腔科学 | 65530篇 |
临床医学 | 215750篇 |
内科学 | 464666篇 |
皮肤病学 | 52914篇 |
神经病学 | 190435篇 |
特种医学 | 90154篇 |
外国民族医学 | 489篇 |
外科学 | 360322篇 |
综合类 | 47641篇 |
现状与发展 | 12篇 |
一般理论 | 877篇 |
预防医学 | 185773篇 |
眼科学 | 55262篇 |
药学 | 178388篇 |
10篇 | |
中国医学 | 4629篇 |
肿瘤学 | 131567篇 |
出版年
2021年 | 19424篇 |
2019年 | 20084篇 |
2018年 | 28123篇 |
2017年 | 21291篇 |
2016年 | 23950篇 |
2015年 | 26547篇 |
2014年 | 37191篇 |
2013年 | 56074篇 |
2012年 | 77281篇 |
2011年 | 82419篇 |
2010年 | 48599篇 |
2009年 | 45587篇 |
2008年 | 77537篇 |
2007年 | 82521篇 |
2006年 | 83068篇 |
2005年 | 80544篇 |
2004年 | 76971篇 |
2003年 | 74402篇 |
2002年 | 71968篇 |
2001年 | 110285篇 |
2000年 | 113415篇 |
1999年 | 94685篇 |
1998年 | 27431篇 |
1997年 | 24041篇 |
1996年 | 24335篇 |
1995年 | 22966篇 |
1994年 | 21173篇 |
1993年 | 19959篇 |
1992年 | 72320篇 |
1991年 | 70336篇 |
1990年 | 68624篇 |
1989年 | 65940篇 |
1988年 | 60521篇 |
1987年 | 59356篇 |
1986年 | 55441篇 |
1985年 | 53274篇 |
1984年 | 39625篇 |
1983年 | 33634篇 |
1982年 | 20085篇 |
1979年 | 36089篇 |
1978年 | 25824篇 |
1977年 | 21415篇 |
1976年 | 20501篇 |
1975年 | 21961篇 |
1974年 | 26274篇 |
1973年 | 24958篇 |
1972年 | 23290篇 |
1971年 | 22121篇 |
1970年 | 20337篇 |
1969年 | 19407篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Mette Nissen Tiina‐Mari Ikheimo Jukka Huttunen Ville Leinonen Henna‐Kaisa Jyrkknen Mikael von und zu Fraunberg 《Neuromodulation》2021,24(1):102-111
ObjectiveSpinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). We studied the effect of preimplantation opioid use on SCS outcome and the effect of SCS on opioid use during a two-year follow-up period.Materials and methodsThe study cohort included 211 consecutive FBSS patients who underwent an SCS trial from January 1997 to March 2014. Participants were divided into groups, which were as follows: 1) SCS trial only (n = 47), 2) successful SCS (implanted and in use throughout the two-year follow-up period, n = 131), and 3) unsuccessful SCS (implanted but later explanted or revised due to inadequate pain relief, n = 29). Patients who underwent explantation for other reasons (n = 4) were excluded. Opioid purchase data from January 1995 to March 2016 were retrieved from national registries.ResultsHigher preimplantation opioid doses associated with unsuccessful SCS (ROC: AUC = 0.66, p = 0.009), with 35 morphine milligram equivalents (MME)/day as the optimal cutoff value. All opioids were discontinued in 23% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.004). Strong opioids were discontinued in 39% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.04). Mean opioid dose escalated from 18 ± 4 MME/day to 36 ± 6 MME/day with successful SCS and from 22 ± 8 MME/day to 82 ± 21 MME/day with unsuccessful SCS (p < 0.001).ConclusionsHigher preimplantation opioid doses were associated with SCS failure, suggesting the need for opioid tapering before implantation. With continuous SCS therapy and no explantation or revision due to inadequate pain relief, 39% of FBSS patients discontinued strong opioids, and 23% discontinued all opioids. This indicates that SCS should be considered before detrimental dose escalation. 相似文献
12.
13.
Hannah C. Nordhues Anjali Bhagra Natya N. Stroud Jennifer A. Vencill Carol L. Kuhle 《Mayo Clinic proceedings. Mayo Clinic》2021,96(7):1907-1920
The coronavirus disease 2019 (COVID-19) pandemic has rapidly created widespread impacts on global health and the economy. Data suggest that women are less susceptible to severe illness. However, sex-disaggregated data are incomplete, leaving room for misinterpretation, and focusing only on biologic sex underestimates the gendered impact of the pandemic on women. This narrative review summarizes what is known about gender disparities during the COVID-19 pandemic and the economic, domestic, and health burdens along with overlapping vulnerabilities related to the pandemic. In addition, this review outlines recommended strategies that advocacy groups, community leaders, and policymakers should implement to mitigate the widening gender disparities related to COVID-19. 相似文献
14.
15.
16.
Immunoglobulin light chain amyloidosis (AL) commonly presents with nephrotic range proteinuria, heart failure with preserved ejection fraction, nondiabetic peripheral neuropathy, unexplained hepatomegaly or diarrhea, and should be considered in patients presenting with these symptoms. More importantly, patients being monitored for smoldering multiple myeloma and a monoclonal gammopathy of undetermined significance (MGUS) are at risk for developing AL amyloidosis. MGUS and myeloma patients that have atypical features, including unexplained weight loss; lower extremity edema, early satiety, and dyspnea on exertion should be considered at risk for light chain amyloidosis. Overlooking the diagnosis of light chain amyloidosis leading to therapy delay is common, and it represents an error of diagnostic consideration. Herein we provide a review of established and investigational treatments for patients with AL amyloidosis and provide algorithms for workup and management of these patients.Subject terms: Myeloma, Chemotherapy 相似文献
17.
18.
Melanie A. Krook Julie W. Reeser Gabrielle Ernst Hannah Barker Max Wilberding Gary Li Hui-Zi Chen Sameek Roychowdhury 《British journal of cancer》2021,124(5):880
Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-nucleotide variants, gene fusions and copy number amplifications in 5–10% of all human cancers, although this frequency increases to 10–30% in urothelial carcinoma and intrahepatic cholangiocarcinoma. We begin this review by highlighting the diversity of FGFR genomic alterations identified in human cancers and the current challenges associated with the development of clinical-grade molecular diagnostic tests to accurately detect these alterations in the tissue and blood of patients. The past decade has seen significant advancements in the development of FGFR-targeted therapies, which include selective, non-selective and covalent small-molecule inhibitors, as well as monoclonal antibodies against the receptors. We describe the expanding landscape of anti-FGFR therapies that are being assessed in early phase and randomised controlled clinical trials, such as erdafitinib and pemigatinib, which are approved by the Food and Drug Administration for the treatment of FGFR3-mutated urothelial carcinoma and FGFR2-fusion cholangiocarcinoma, respectively. However, despite initial sensitivity to FGFR inhibition, acquired drug resistance leading to cancer progression develops in most patients. This phenomenon underscores the need to clearly delineate tumour-intrinsic and tumour-extrinsic mechanisms of resistance to facilitate the development of second-generation FGFR inhibitors and novel treatment strategies beyond progression on targeted therapy.Subject terms: Cancer, Cancer 相似文献
19.
20.